Guardian Pharmacy Services, Inc. (GRDN) Stock Forecast
GRDN analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.86 / 5 from 7 analysts
- Price target
- $49.86 average of analyst targets
- Upside to target
- +26.3% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $0.28
- 52-week range
- $25.89 – $48.00
GRDN analyst ratings
7 analystsNumber of analysts at each rating.
GRDN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
GRDN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.31 | $0.29 | $0.33 | $0.25 | +25.7% | 7 |
| Current fiscal year (2026) | $1.30 | $1.25 | $1.34 | $1.07 | +21.6% | 7 |
| Next fiscal year (2027) | $1.43 | $1.36 | $1.49 | $1.30 | +10.2% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
GRDN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $365.8M | $362.8M | $368.7M | −3.1% | 7 |
| Current fiscal year (2026) | $1.44B | $1.44B | $1.45B | −0.5% | 7 |
| Next fiscal year (2027) | $1.53B | $1.50B | $1.60B | +6.3% | 7 |
GRDN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
GRDN revenue: reported and forecast
GRDN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.30 | $0.32 | $0.32 | $0.31 | $0.31 | +4.2% | 4 up · 0 down |
| Current fiscal year (2026) | $1.26 | $1.30 | $1.30 | $1.30 | $1.30 | +3.3% | 4 up · 0 down |
| Next fiscal year (2027) | $1.36 | $1.43 | $1.43 | $1.43 | $1.43 | +5.6% | 5 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
GRDN earnings surprises
Reported EPS vs the consensus estimate for the last 9 quarters; GRDN beat in 8 of 9.
What analysts expect from GRDN
7 analysts cover Guardian Pharmacy Services; their consensus rating is strong buy (4.86 on a 1–5 scale, where 5 is a strong buy). The average price target is $49.86, 26.3% above the latest close of $39.47. Analysts expect earnings of $1.30 per share for 2026, +21.6% from a year earlier. For 2027 the average estimate is $1.43 per share on revenue of $1.5 billion. Guardian Pharmacy Services beat the EPS estimate in 8 of the last 9 quarters.
Related: GRDN income statement, GRDN key metrics, GRDN chart. See the GRDN stock overview for the latest quote and news.
GRDN forecast FAQ
What is Guardian Pharmacy Services's price target?
The average analyst price target for Guardian Pharmacy Services is $49.86, 26.3% above the latest close of $39.47.
Is Guardian Pharmacy Services a buy, hold or sell?
Of 7 analysts covering Guardian Pharmacy Services, 6 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Guardian Pharmacy Services's EPS forecast?
Analysts forecast $1.30 per share for 2026 (range $1.25 to $1.34); for 2027 the estimate is $1.43.
What is Guardian Pharmacy Services's revenue forecast?
The average revenue estimate for 2026 is $1.4 billion, growth of −0.5%; for 2027 it is $1.5 billion.
When does Guardian Pharmacy Services report earnings?
Guardian Pharmacy Services is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes; the EPS estimate is $0.28.
Does Guardian Pharmacy Services usually beat earnings estimates?
Guardian Pharmacy Services reported EPS at or above the analyst estimate in 8 of the last 9 quarters.